Insulet (PODD) to Release Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $1.20 per share and revenue of $729.90 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same quarter in the previous year, the firm earned $1.15 earnings per share. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, analysts expect Insulet to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Insulet Trading Down 2.9%

Shares of Insulet stock opened at $182.87 on Wednesday. The firm has a market cap of $12.67 billion, a price-to-earnings ratio of 52.25, a price-to-earnings-growth ratio of 1.13 and a beta of 1.47. Insulet has a 52-week low of $182.25 and a 52-week high of $354.88. The company’s 50-day simple moving average is $219.87 and its 200-day simple moving average is $269.26. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PODD shares. BTIG Research dropped their target price on Insulet from $380.00 to $320.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Truist Financial reduced their price target on Insulet from $360.00 to $315.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. TD Cowen downgraded Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a research note on Monday, January 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $325.00 price objective on shares of Insulet in a report on Tuesday, April 14th. Finally, Barclays reissued an “underweight” rating and issued a $286.00 target price on shares of Insulet in a report on Thursday, February 19th. Eighteen equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $327.24.

Insider Activity

In other news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the purchase, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. Glenmede Investment Management LP boosted its position in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 35 shares in the last quarter. Curi Capital LLC increased its position in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares in the last quarter. Great Lakes Advisors LLC increased its position in shares of Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after buying an additional 40 shares in the last quarter. Camarda Financial Advisors LLC raised its stake in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after buying an additional 40 shares during the last quarter. Finally, Hilltop Holdings Inc. raised its stake in shares of Insulet by 1.6% during the 3rd quarter. Hilltop Holdings Inc. now owns 2,896 shares of the medical instruments supplier’s stock worth $894,000 after buying an additional 47 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.